🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInsurance & AccessVA healthcare GLP-1 access — September 2026

VA healthcare GLP-1 access — September 2026

mike_mod Wed, Feb 18, 2026 at 3:51 PM 23 replies 1,068 viewsPage 1 of 5
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Feb 18, 2026 at 3:51 PM#1

Posting this because the summary going around does not say what the paper says, and the difference matters for how people here are using it.

Denials are usually procedural rather than clinical, and the order that works reflects that. Get the denial reason in writing, because it names the criterion you failed. Then supply the documentation that criterion asks for — usually documented BMI with a comorbidity, or a failed prior therapy. Then appeal, and ask for a peer-to-peer review, because a prescriber talking to a reviewing clinician resolves a large fraction of denials that written appeals do not. Manufacturer copay assistance is separate and applies mainly to commercial insurance, and patient assistance programmes are means-tested rather than a discount.

Where I think it is weakest: the comparator does most of the work in how this gets reported, and it is not the comparator most people think they are citing.

What I am after is what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work. I would rather have one careful answer than five confident ones.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
11 6PharmHunterJen, TomTeleRx, DoseLogDan and 8 others
Reply Quote Save Share Report
pete_manc_UK
Senior Member
1,234
5,678
Mar 2024
Manchester, UK
Feb 18, 2026 at 4:45 PM#2
mike_mod said:
Denials are usually procedural rather than clinical, and the order that works reflects that.
mike_mod said:
...my insurance denied cost and coverage coverage because...

Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:

  1. Document medical necessity (BMI, comorbidities, failed alternatives)
  2. Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
  3. Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
  4. Request peer-to-peer review between your doctor and the plan's medical director
  5. File external appeal with your state insurance department if internal appeal fails

Don't accept the first denial. The appeal process exists for a reason.

10 5RunnerRach, TrialNerd_Beth, HPLC_Greg and 7 others
Reply Quote Save Share Report
DebRD_ATL
Senior Member
1,678
7,890
Feb 2024
Atlanta, GA
Feb 18, 2026 at 5:39 PM#3
mike_mod said:
Denials are usually procedural rather than clinical, and the order that works reflects that.

I read this differently from mike_mod, on substance rather than tone. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.

9 4SleepDoc_PDX, RegAffairsDC, BiostatsBrad and 6 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
newstart_MO
New Member
12
45
Feb 2026
Springfield, MO
Feb 18, 2026 at 6:33 PM#4
DebRD_ATL said:
The affordability discussion here usually stops at individual tactics.

Insurance update relevant to cost and coverage: I just got my prior auth approved through Aetna after 4 attempts.

What finally worked: a letter from my endocrinologist documenting BMI history (>3 years), failed diet attempts, comorbidities (NAFLD + metabolic syndrome), and referencing the SURMOUNT trial data.

If your PA keeps getting denied, don't give up. Request a peer-to-peer review between your doctor and the insurance medical director. That's what finally broke through for me.

8 3TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 5 others
Reply Quote Save Share Report
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
Feb 18, 2026 at 11:43 PM#5
pete_manc_UK said:
mike_mod said: ...my insurance denied cost and coverage coverage because...

Adding a me-too, because a thread of one person's experience is not much use.

Last edited: Feb 19, 2026 at 1:43 AM
7 2tampaLisa73, KarenAZ_mom, zoe_NC and 4 others
Reply Quote Save Share Report
1235

Similar Threads

Prior authorization success: step-by-step guide with templates5 replies
Cigna now covering Zepbound — how I got approved13 replies
Appeal letter template — denied PA for GLP-1 medications4 replies
Mounjaro savings card — manufacturer program changes 202610 replies
Medicare Part D GLP-1 coverage — what's covered in 202610 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register